What does CeriBell do and what are its main business segments?

What were the key takeaways from CeriBell’s earnings call?

What is CeriBell's gross profit margin?

What factors drove the changes in CeriBell's revenue and profit?

What is CeriBell's latest dividend and current dividend yield?

What were the key takeaways from CeriBell's earnings call?

What is the market's earnings forecast for CeriBell next quarter?

What guidance did CeriBell's management provide for the next earnings period?

- **Revenue Growth**: Q3 2025 revenue up 31% YoY to $22.6 million; full-year guidance raised to $87-89 million. 
- **Market Penetration**: 615 active accounts (31 new Q3), targeting 200+ NICUs and 280 children's hospitals. 
- **Clinical Validation**: Pediatric Clarity algorithm shows 94.4% sensitivity in 645 patients; neonatal headcap cleared for preterm/term infants. 
- **Financial Strength**: $168.5 million cash; mid-80s gross margin expected for FY2026. 
- **Strategic Wins**: VA system partnership, neonatal product pipeline ($400M incremental market).

**【CEO Summary Section】**
- Q3 2025 revenue: $22.6 million (31% YoY growth), driven by 31 new active accounts (total 615). 
- Raised full-year 2025 guidance to $87-89 million (34% YoY growth). 
- Expanded into VA system with FedRAMP High Authorization; VA pilot shows intent for broader rollout. 
- Pediatric Clarity algorithm demonstrates 94.4% sensitivity, 93.1% specificity in 645 patients. 
- Neonatal headcap cleared for preterm and term infants; full neonatal Clarity launch planned for 2026. 
- Penetration: 10% of U.S. acute care hospitals, 30% within active accounts, 3% of total addressable market.

**【CFO Financial Commentary】**
- Product revenue: $17 million (28% YoY), Subscription: $5.6 million (44% YoY). 
- Gross margin: 88% (vs. 87% YoY), maintained despite tariffs via Vietnam manufacturing line. 
- Operating expenses: $34.6 million (39% YoY), driven by commercial expansion. 
- Cash reserves: $168.5 million; no plans to raise capital. 
- Q4 2025 gross margin expected to remain mid-80s; FY2026 guidance for mid-80s gross margin.

**【Q&A Highlights】**
- **2026 Outlook**: Management declines to provide 2026 guidance, but cites account additions and utilization as key drivers. 
- **Neonatal Launch**: 200 existing NICU accounts will adopt departmentally; 280 children's hospitals represent new account opportunity. 
- **Utilization Growth**: Tenured accounts growing via protocol adoption (stroke, cardiac arrest), departmental expansion (ED, step-down units). 
- **Competition**: Increased competitive activity in 2025, but Ceribell maintains momentum with superior clinical evidence and cybersecurity. 
- **VA Expansion**: First phase of VA rollout planned for next quarters, leveraging successful pilot results.

CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CBLL

CBLL fundamentals

You can ask Aime